Aduhelm verdict puts the heat on Biogen – and on the FDA
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
JP Morgan 2022 roundup – Biogen in focus
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Your 2022 wildcard predictions revealed
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Novartis eyes up another gene therapy
The company is making a high-risk, high-reward bet with the purchase of Gyroscope.
Sanofi moves further into next-gen oncology
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Free to download now: Evaluate Vantage’s 2022 Preview
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.
